ALDH1 bio-activates nifuroxazide to eradicate ALDH<sup>High</sup> melanoma-initiating cells by Sarvi, Sana et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ALDH1 bio-activates nifuroxazide to eradicate ALDH(High)
melanoma-initiating cells
Citation for published version:
Sarvi, S, Crispin, R, Lu, Y, Zeng, L, Hurley, TD, Houston, D, von Kriegsheim, A, Chen, C-H, Mochly-Rosen,
D, Ranzani, M, Mathers, ME, Xu, X, Xu, W, Adams, DJ, Carragher, N, Fujita, M, Schuchter, L, Unciti-
Broceta, A, Brunton, V & Patton, E 2018, 'ALDH1 bio-activates nifuroxazide to eradicate ALDH(High)
melanoma-initiating cells' Cell Chemical Biology. DOI: 10.1016/j.chembiol.2018.09.005
Digital Object Identifier (DOI):
10.1016/j.chembiol.2018.09.005
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Version created as part of publication process; publisher's layout; not normally made publicly available
Published In:
Cell Chemical Biology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Article
ALDH1 Bio-activates Nifuroxazide to Eradicate
ALDHHigh Melanoma-Initiating CellsGraphical AbstractHighlightsd ALDH1 bio-activates nifuroxazide leading to ALDH1
inactivation and cytotoxicity
d Nifuroxazide selectively eradicates ALDH1High melanoma
tumor-initiating cells
d Targeted therapy increases ALDH1 in some patient
melanomas and cell line models
d Targeting ALDH1High cells with nifuroxazide is an orthogonal
therapeutic strategySarvi et al., 2018, Cell Chemical Biology 25, 1–14
December 20, 2018 ª 2018 The Authors. Published by Elsevier L
https://doi.org/10.1016/j.chembiol.2018.09.005Authors
Sana Sarvi, Richard Crispin,
Yuting Lu, ..., Asier Unciti-Broceta,
Valerie G. Brunton, E. Elizabeth Patton
Correspondence
e.patton@igmm.ed.ac.uk
In Brief
A major challenge for cancer treatment is
that tumors are comprised of
subpopulations with differing growth
potential and drug sensitivity. Here, Sarvi
and colleagues reveal that the clinically
approved antibiotic, nifuroxazide,
selectively eliminates ALDH1High
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5-Nitrofurans are antibiotic pro-drugs that have
potential as cancer therapeutics. Here, we show that
5-nitrofurans can be bio-activated by aldehyde dehy-
drogenase (ALDH) 1A1/1A3 enzymes that are highly
expressed in a subpopulation of cancer-initiating
(stem)cells.Wediscover that the5-nitrofuran,nifurox-
azide, is selective for bio-activation by ALDH1 iso-
forms over ALDH2, whereby it both oxidizes ALDH1
and is converted to cytotoxic metabolites in a two-
hit pro-drug mechanism. We show that ALDH1High
melanoma cells are sensitive to nifuroxazide, while
ALDH1A3 loss-of-function mutations confer drug
resistance. In tumors, nifuroxazide targets ALDH1High
melanoma subpopulations with the subsequent loss
of melanoma-initiating cell potential. BRAF and MEK
inhibitor therapy increases ALDH1 expression in
patient melanomas, and effectively combines with
nifuroxazide in melanoma cell models. The selective
eradication of ALDH1High cells by nifuroxazide-
ALDH1 activation goes beyond current strategies
basedon inhibiting ALDH1andprovides a rational ba-
sis for thenifuroxazidemechanismofaction incancer.
INTRODUCTION
5-Nitrofurans are pro-drugs (i.e., they require bio-activation for
activity) and have been widely used in human and veterinaryCell Chemical Biology 25, 1–14, De
This is an open access article under the CC BY-Nmedicine for over 40 years to treat bacterial and trypanosome
infections (Clayton, 2010). Recently, 5-nitrofuran antibiotics,
such as nifurtimox and nifuroxazide, have been found to have
anti-cancer activity in cancers, including neuroblastoma, mela-
noma, multiple myeloma, colon, and breast cancer (Nelson
et al., 2008; Saulnier Sholler et al., 2006, 2011; Yang et al.,
2015; Ye et al., 2017; Zhou et al., 2012; Zhu et al., 2016).
Notably, nifurtimox reduced neuroblastoma tumor burden in a
child with Chagas disease caused by trypanosome infection
(Saulnier Sholler et al., 2006), and is now in a phase II clinical
trial to treat children with relapsed or refractory neuroblastoma
or medulloblastoma (NCT00601003) (Saulnier Sholler et al.,
2011). When used to treat infectious disease, the relative selec-
tivity of the 5-nitrofurans is mediated by bio-activation by bac-
terial- or parasite-specific nitroreductases (Clayton, 2010).
However, the mechanism by which 5-nitrofurans confer anti-
cancer activity is not well understood, limiting efforts for
5-nitrofuran drug development, patient stratification, and the
development of treatment strategies.
We previously discovered that aldehyde dehydrogenase 2
(ALDH2) is a direct target for nifurtimox and NFN1 (a tool com-
pound featuring a 5-nitrofuran moiety) by a small-molecule
phenotypic screen in zebrafish (Zhou et al., 2012). ALDH
enzymes are a large family of enzymes that metabolize toxic al-
dehydes (Koppaka et al., 2012; Ma and Allan, 2011). ALDHHigh
activity marks somatic stem cells, and, in many cancers, cells
with ALDHHigh enzymatic activity have enhanced tumorigenic
potential and mark so-called cancer stem cell subpopulations
(Marcato et al., 2011; Tomita et al., 2016). Cancer cell hetero-
geneity, including cancer stem cell populations, is of clinical
importance because it can make treatment difficult, drive tumor
progression, and promote drug resistance (Kreso and Dick,cember 20, 2018 ª 2018 The Authors. Published by Elsevier Ltd. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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especially important in melanoma, where a majority of patients
with metastatic melanoma succumb to the disease, and even
those who initially respond to targeted or immune treatment
may eventually die due to melanoma recurrence and drug resis-
tance (Luke et al., 2017).
Despite the prevalence of the ALDHHigh subpopulations in
multiple cancer types, there are no clinically available drugs
that specifically target such subpopulations. Clinically active
ALDH inhibitors, such as disulfiram or daidzin, are strong inhibi-
tors for ALDH2, the principal ALDH enzyme responsible for
alcohol metabolism, as well as other possible targets (Kona
et al., 2011; Koppaka et al., 2012), whereas ALDHHigh activity
in melanoma is mediated by ALDH1A1 and ALDH1A3 (Luo
et al., 2012; Yue et al., 2015). Further, ALDH1 inhibitors, although
able to reduce enzyme activity, are not designed to eradicate
ALDH1High subpopulations (Koppaka et al., 2012; Tomita
et al., 2016).
We hypothesized that ALDH1 might bio-activate certain
5-nitrofuran derivatives and thereby eradicate ALDH1High mela-
noma-initiating subpopulations in tumors. Here, we report that
5-nitrofurans are bio-activated by ALDH1 and show that nifurox-
azide, a clinically approved 5-nitrofuran pro-drug, is selectively
bio-activated by ALDH1 enzymes over ALDH2 enzymes. This
interaction is critical to mediate nifuroxazide anti-tumor activity.
Nifuroxazide-induced loss of ALDH1High subpopulations has a
direct impact on the melanoma-initiating (cancer stem) cell po-
tential in tumors. This is of clinical importance because we
show that BRAF inhibitors lead to an increase in ALDH1High mel-
anoma cells in matched patient biopsies in recurrent metastatic
melanoma, and that BRAF inhibitors plus MEK inhibitors lead to
an increase in ALDH1A1 mRNA in matched patient biopsies
while on treatment.
Our work argues that an important mechanism of action for ni-
furoxazide in cancer is through the eradication of ALDH1High
cells. These findings lead to two conceptual advances in mela-
noma therapy that may also be applied more widely to cancer
therapy: (1) to selectively kill ALDH1High cell subpopulations,
rather than inhibit ALDH1 enzymatic activity, and (2) that the tu-
mor-initiating and stem cell properties of cancer subpopulations
can be drug targets, rather than targeting the molecular activity
of cancer mutations.
RESULTS
ALDH1 Is a Selective Target for Nifuroxazide
We have previously demonstrated that 5-nitrofuran pro-drugs
can be substrates for, and bio-activated by, ALDH2 enzymes,
leading to DNA damage and reactive oxygen species to kill can-
cer cells (Zhou et al., 2012). This prompted us to test if 5-nitro-
furan might be bio-activated by ALDH1, yielding an opportunity
to specifically target ALDH1High melanoma subpopulations.
To establish the range of concentration of drug activity in
cells, we first tested four clinical 5-nitrofurans (nifuroxazide, ni-
trofurantoin, furazolidone, and nifurtimox), our 5-nitrofuran tool
compound NFN1, and the inactive no-nitro control compound
NFN1.1 (in which a hydrogen atom replaces the nitro moiety)
(Figures 1A, S1A, and S1B). Among the clinical compounds,
we found nifuroxazide to have the lowest half maximal effective2 Cell Chemical Biology 25, 1–14, December 20, 2018concentration (EC50) value in A375 melanoma cell lines and
used nifuroxazide as a clinical 5-nitrofuran in our subsequent
studies.
Next, we tested the potential for nifuroxazide and NFN1 to be
substrates for ALDH1 and ALDH2 enzymes in vitro. If 5-nitrofu-
rans are bio-activated by ALDH1, they will compete for ALDH ac-
tivity toward aldehyde substrates. In this assay, ALDH enzymes
metabolize aldehydes and convert NAD+ to NADH. Test sub-
strates that compete for ALDH activity toward aldehydes lead
to a reduction in NADH production. As positive controls, we
used the ALDH1/2 inhibitor disulfiram, or the potent ALDH2 in-
hibitor daidzin (Koppaka et al., 2012). We found that both nifur-
oxazide and the NFN1 tool compound were effective substrates
for the ALDH1 isoform ALDH1A3 (Figure 1B), which is highly ex-
pressed in melanoma-initiating cell lines.
Surprisingly, while the NFN1 tool compound was a substrate
for both ALDH1 and ALDH2 enzymes, nifuroxazide was not an
effective substrate for ALDH2 (Figure 1B). These results were
validated in a zebrafish ALDH2 activity assay (Figure S1C)
(Zhou et al., 2012). Zebrafish melanocytes express ALDH2,
and treatment with nifuroxazide (up to 30 mM) did not show
any toxicity toward zebrafish melanocytes, whereas treatment
with NFN1 (10 mM) significantly reduced the number of melano-
cytes. To further explore the different selectivity for ALDH2 at
equimolar concentrations, we purified ALDH2 and tested its ac-
tivity with increasing concentrations of NFN1 and nifuroxazide.
Dose-curve analysis revealed NFN1 is a highly selective for
ALDH2 (NFN1IC50 = 63.9 nM), while nifuroxazide had no activity
toward ALDH2 up to 10 mM (Figure S1D). Thus, the antibiotic
nifuroxazide is a selective substrate for ALDH1.
Next, we used the Aldefluor assay to determine if nifuroxa-
zide might be a substrate of, and modulate, ALDH1 activity in
melanoma cells. The Aldefluor assay is based on ALDH enzyme
activity to convert the freely diffusible fluorescent BODIPY-ami-
noacetaldehyde to the negatively charged BODIPY-aminoace-
tate that is retained and accumulates in the cell. A375
melanoma cell lines are heterogeneous for ALDH activity, with
cells presenting low, intermediate, and high fluorescence for Al-
defluor activity, which can be seen by fluorescence microscopy
(Figure 1C) and used to isolate ALDHHigh and ALDHLow subpop-
ulations by fluorescence-activated cell sorting (FACS) (Fig-
ure 1D). ALDH activity heterogeneity is due, at least in part,
to increased mRNA expression of ALDH1A3 in the ALDHHigh
subpopulation compared with the ALDHLow subpopulation (Fig-
ure 1E). Nifuroxazide and NFN1 effectively reduced Aldefluor
activity (Figure 1F), indicating that nifuroxazide inhibits ALDH
enzyme activity in cells. Inhibition of Aldefluor activity was
dependent on the 5-nitro moiety because our no-nitro control
compound (NFN1.1) had no effect on ALDH activity in cells
(Figure S1E).
To test if 5-nitrofuran activity toward ALDH was linked to the
mechanism ofmelanoma cell death, we tested if N,N-diethylami-
nobenzaldehyde (DEAB) could prevent 5-nitrofuran cytotoxic
activity in cells. DEAB is a potent inhibitor of ALDH1, but also
has broad inhibitor activity toward other ALDH enzymes (Kop-
paka et al., 2012; Luo et al., 2012; Moreb et al., 2012). We found
that DEAB pre-treatment protected the cells from the cytotox-
icity of NFN1 (Figure 1G). These data indicate that 5-nitrofuran
pro-drug cytotoxicity is dependent on ALDH activity.
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Figure 1. ALDH1 Is a Selective Target for Nifuroxazide
(A) Chemical structures of 5-nitrofuran compounds.
(B) ALDH1A3 and ALDH2 in vitro activity assay, with addition of 5-nitrofurans and ALDH inhibitors. Values represent the percent NADH production relative to the
DMSO control. Values are means ± SEM (n = 3; *p < 0.05; **p < 0.01; ***p < 0.001, ns, not significant, Student’s t test with Dunnett’s post-test). Nifuroxazide (NAZ)
(10 mM), NFN1 (1 mM), disulfiram (10 mM), and daidzin (10 mM). Schematic diagram indicates mechanism of NAD+ reduction to NADH by ALDH activity.
(C) Heterogeneity for Aldefluor activity in A375 cells. ALDHHigh, ALDHLow, and ALDHIntermediate are indicated (arrows).
(D) Flow cytometry histogram demonstrating Aldefluor activity in A375 unsorted cells and sorted ALDHHigh and ALDHLow cells.
(E) qRT-PCR for ALDH1A3 RNA expression in FACS sorted ALDHHigh and ALDHLow subpopulations. Values are normalized to GAPDH RNA expression. Values
are means ± SEM (n = 3; Student’s t test).
(F) Aldefluor activity in A375 cells treated with 1 mM NFN1, 10 mM nifuroxazide, or DMSO control for 24 hr (n > 3). DEAB used as negative control.
(G) Sensitivity of A375 cells to NFN1 +/DEAB. Cytotoxicity was evaluated by Draq7 expression using IncuCyte Zoom. Values are means ± SEM (n = 3; *p < 0.05;
**p < 0.01, ANOVA with Tukey’s test).
See also Figure S1.
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Inhibition of ALDH1 Enzymes
ALDH1A1 and ALDH1A3 are closely related enzymes and are the
predominant ALDH1 isoforms in primary melanoma and mela-noma cell lines (Luo et al., 2012). To address the molecular
mechanism of how nifuroxazide interacts with ALDH1 enzymes,
we first used molecular modeling. The ALDH1A3 structure has
recently been solved (Moretti et al., 2016) and our analysisCell Chemical Biology 25, 1–14, December 20, 2018 3
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Figure 2. Nifuroxazide Bio-activation Leads to Oxidation and Inhibition of ALDH1 Enzymes
(A and B) Molecular modeling of ALDH1A3 with nifuroxazide (NAZ) and NAD. Nifuroxazide (color filled) forms molecular bonds with the cysteines 313,314 in the
active site.
(C and D) Mass spectrometry traces of ALDH1A1 and NAD (C), and ALDH2 and NAD (D) in combination with 5-nitrofurans and control compounds or DMSO. Red
arrows indicate oxidized ALDH1A1 and ALDH2 species, black arrows indicate enzyme-5-nitrofuran adducts.
(E) Liquid chromatography-tandem mass spectrometry (LC-MS/MS) quantitative analysis of oxidation of the catalytic cysteines in the active center of ALDH1A1
with nifuroxazide. Values are normalized by dividing the intensity of the oxidized peptide over the sum of all intensities of all peptides identified in the protein
(ratio ox-pep/protein) (*p < 0.05, Student’s t test).
(F) Schematic diagram of nifuroxazide two-hit mechanism of action. ALDH1 enzymes bio-activate the nifuroxazide pro-drug, leading to reactive nitro species
(*Nifuroxazide) and cell toxicity, and concomitantly oxidize and inactivate ALDH1.
See also Figure S2.
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pocket of ALDH1A3, predicting direct interactions with cysteines
313 and 314 in the active site (Figures 2A and 2B).
To address the potential of 5-nitrofurans to interact with
ALDH1A1, we incubated ALDH1A1 with the 5-nitrofurans and4 Cell Chemical Biology 25, 1–14, December 20, 2018performed mass spectrometry of the intact protein (Figure 2C).
The results showed ALDH1A1 mass increasing by +35 atomic
mass units (amu), consistent with a di-oxidation with nifuroxa-
zide plus NAD+ (42% oxidation of total protein) or NFN1 plus
NAD+ (80%oxidation of total protein). In comparison, incubation
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(A) Western blot of ALDH1A3 in ALDH1A3 siRNA transfected A375 (si1A3) cells, siRNA control (siCon), and wild-type (WT) control cells. GAPDH, loading control.
(B) Aldefluor activity in si1A3 cells or siCon cells. DEAB was used as a negative control (n > 3).
(C) Sensitivity of si1A3 and siCon cells to NFN1 measured by levels of Draq7 expression using IncuCyte Zoom. Values are means ± SEM (n = 3, ****p < 0.0001,
ANOVA with Tukey’s test).
(D) Western blot of ALDH1A3 protein in ALDH1A3 knockout single-cell clones. GAPDH, loading control (n > 3).
(E) Aldefluor activity in ALDH1A3 knockout clones and A375-Cas9 WT cells. DEAB is used as negative control.
(F) Sensitivity of ALDH1A3Cpr3 and A375-Cas9 cells to 10 mM nifuroxazide measured by levels of Draq7 expression using IncuCyte Zoom. Values are means ±
SEM (n = 4, ***p < 0.001, ANOVA).
(G) Representative images of WT and ALDH1A3Cpr3 cells treated with nifuroxazide or DMSO, imaged with IncuCyte Zoom. Note cell death in upper panel.
(legend continued on next page)
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Biology (2018), https://doi.org/10.1016/j.chembiol.2018.09.005of ALDH2 with nifuroxazide plus NAD+ did not generate the
observed mass shift, while NFN1 plus NAD+ generated both a
31-amu shift and a possible ALDH2-NFN1 adduct (+338 amu)
(Figure 2D). The nitromoiety is essential for this process because
incubation of NFN1.1 did not generate any additional species
with either enzyme (Figures 2C and 2D). Likewise, oxidation of
ALDH enzymes by 5-nitrofurans was dependent on NAD+
(Figure S2).
We then used liquid chromatography-tandem mass spec-
trometry to determine the site of nifuroxazide-catalyzed modifi-
cation. Quantitative analysis of the modification revealed a
significant increase in the oxidation of the catalytic cysteine in
the active center of ALDH1A1 upon the addition of nifuroxazide
(Figure 2E).
Together, these results demonstrate that nifuroxazide directly
and specifically interacts with the ALDH1A1 and ALDH1A3 iso-
forms leading to oxidation and inactivation of ALDH1 isozymes
at the catalytic core. Thus, unlike ALDH1 enzymatic inhibitors,
nifuroxazide has a unique two-hit mechanism whereby bio-acti-
vation of nifuroxazide by ALDH1 enzymes leads to cytotoxicity
concomitant with ALDH1 inactivation (Figure 2F). Nifuroxazide
pro-drugs provide an opportunity to move beyond inhibiting
ALDH1 enzymes in cancer cells, to selectively eradicating
ALDH1-expressing cells in melanoma.
Nifuroxazide Bio-activation Is Mediated by ALDH1A3
Primarymelanoma samples express high levels of ALDH1A1 and
ALDH1A3, but ALDH1A3 is the predominant form in A375 mela-
noma cell lines (Luo et al., 2012). If the 5-nitrofuran-ALDH1 inter-
action is relevant in vivo, we would expect that loss of ALDH1
would confer resistance to 5-nitrofuran treatment. Small inter-
fering RNA (siRNA) knockdown of ALDH1A3 transcripts reduced
ALDH1A3 protein levels and Aldefluor activity, and validates
ALDH1A3 as the dominant ALDH1 enzyme responsible for Alde-
fluor activity in melanoma A375 cells (Figures 3A and 3B). Next,
we tested the sensitivity of these cells to NFN1, and found siRNA
ALDH1A3 cells to have significantly reduced sensitivity to NFN1
toxicity (Figure 3C).
Further, we generated ALDH1A3 mutant lines using CRISPR/
Cas9, and selected two single-cell clones (ALDH1A3Cpr3 and
ALDH1A3Cpr21) that are predicted to be truncated in the N termi-
nus and showed reduced ALDH1A3 protein expression (Figures
3D and S3A) and Aldefluor activity (Figure 3E). Notably,
ALDH1A3Cpr3 and ALDH1A3Cpr21 cell lines had no apparent
growth phenotype in culture, and grew at the same rate as con-
trol cells indicating that ALDH1A3 is not essential for cell growth
in A375 cell culture (Figure S3B). However, ALDH1A3Cpr3 and
ALDH1A3Cpr21 cells had significantly reduced clonogenic poten-
tial in soft agar, an assay that tests the ability of a single-cell
clonal growth in a 3D environment (Figure S3C) and were unable(H) Clonogenic potential of ALDH1A3Cpr3, ALDH1A3Cpr21, and control A375-Cas9
ANOVA with Dunnett’s test).
(I) Western blot image of ALDH1A3 protein levels in A375 cells overexpressing A
GAPDH, loading control.
(J) Aldefluor activity in ttALDH1A3 and WT control. DEAB was used as negative
(K and L) Sensitivity of A375 (K) and C089 (L) cells, control and overexpressing A
means ± SEM (n = 3).
See also Figure S3.
6 Cell Chemical Biology 25, 1–14, December 20, 2018to form tumors in xenografts (Figure S3D), consistent with the
concept that ALDHHigh subpopulations have functional tumor-
initiating characteristics in melanoma cells. Importantly, we
found thatALDH1A3Cpr3 andALDH1A3Cpr21 cell lines were resis-
tant to nifuroxazide and NFN1 in cell growth (2D culture) and
colony cultures (3D culture) (Figures 3F–3H and S3E–S3H).
Given that loss of ALDH1A3 made cells resistant to nifuroxa-
zide, we hypothesized that overexpression of ALDH1 should
increase cell sensitivity to nifuroxazide. We overexpressed
ALDH1A3 in A375 and C089 melanoma cells by transient trans-
fection, and found that the cells were more sensitive to nifurox-
azide than control cells (Figures 3I–3L).
Thus, our genetic analysis confirms that the cytotoxic activity
of nifuroxazide in these melanoma cells is mediated by ALDH1,
and not an otherwise unknown target enriched in the ALDHHigh
subpopulation. By extension, and in combination with our
in vitro assays in Figures 1 and 2, it is likely that nifuroxazide is
bio-activated in cancers by other ALDH1 isoforms including
ALDH1A1.
Nifuroxazide Selectively Kills ALDHHigh Subpopulations
Having established that ALDH1 enzymes are targets for nifurox-
azide in cells, we wanted to test if nifuroxazide is selectively
cytotoxic for ALDHHigh tumor-initiating (stem cell-like) subpopu-
lations. First, we FACS sorted the top 5% of cells highly express-
ing ALDH enzyme activity (ALDHHigh cells) and the bottom 5% of
cells with the lowest ALDH enzyme activity (ALDHLow cells) (see
Figure 1D). The ALDHHigh cell population had increased sphere-
forming potential, which was further increased following serial
passage (Figure S4A) andweremore efficient at forming colonies
in soft agar (Figure 4A). ALDHHigh cells also had the potential to
differentiate into ALDHIntermediate and ALDHLow cells over time
while maintaining an ALDHHigh population, whereas ALDHLow
cells were unable to form ALDHHigh populations (Figure S4B).
In addition, in vivo, ALDHHigh cells were more tumorigenic than
the ALDHLow cells (Figure S4C). Together, these data validate
that the top 5% of ALDHHigh cell populations are enriched for
phenotypic properties associated with stemness and melanoma
tumor-initiating potential.
Having separated the cells into ALDHLow and ALDHHigh popu-
lations, and validated their cellular phenotypes, we then tested
soft agar colonies derived from each population to increasing
concentrations of nifuroxazide and NFN1 (Figures 4B and
S4D). We used lower concentrations of drug treatments for the
colony assay because the single cells are grown in anchorage-
independent conditions and are treated over 21 days to develop
into colonies. ALDHHigh-derived colonies were highly sensitive to
nifuroxazide and NFN1. In contrast, colonies generated from
ALDHLow cells, while producing fewer colonies overall, were
resistant to NFN1 and nifuroxazide treatment.cells in soft agar. Values are means ± SEM (n = 3, ***p < 0.001, ****p < 0.0001,
LDH1A3 (transient transfection ALDH1A3 [ttALDH1A3]) and WT control cells.
control.
LDH1A3 to nifuroxazide. Viability was measured using SRB assay. Values are
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See also Figure S4.
Please cite this article in press as: Sarvi et al., ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells, Cell Chemical
Biology (2018), https://doi.org/10.1016/j.chembiol.2018.09.005We tested if the paradigm of ALDHHigh activity and nifuroxa-
zide sensitivity can be extended to melanoma cell lines repre-
sentative of different melanoma genetic subtypes. We tested
Aldefluor activity and nifuroxazide sensitivity in four additional
melanoma cell lines: C089 (BRAFV600E), C077 (NF1mut), MEWO
(NF1mut), and C092 (triple wild-type) (Ranzani et al., 2015). Alde-
fluor activity varied widely among cell lines, independently of
genetic subtype (Figures 4C and S4E). We found that cell lines
with relatively high median levels of ALDH activity formed col-
onies and were highly sensitive to nifuroxazide (Figures 4D and
S4F). In contrast, cells with relatively low median levels of
ALDH activity had very low colony formation potential and
were resistant to nifuroxazide (Figures 4D and S4F).
Thus, nifuroxazide has selective activity toward multiple cell
lines with overall relatively high ALDH activity, and this is inde-
pendent of melanoma genetic subtype.
Nifuroxazide Targets ALDH1High Subpopulations in
Tumors
Ultimately, we wanted to establish if ALDHHigh subpopulations
are selective targets for nifuroxazide in vivo and impact tumor
growth. We performed a melanoma xenograft assay with human
melanoma cells that express a tdTomato transgene (A375-L2T
cells) enabling us to isolate melanoma cells following treatment.
Once the tumors were established, mice were treated with nifur-
oxazide or with oil vehicle. Nifuroxazide significantly attenuated
tumor growth (>10 tumors) (Figures 5A and 5B). We also tested
if nifuroxazide could be effective at lower treatment concentra-
tions, and treated A375 melanoma xenografts with 50 or
150 mg/kg for 13 days. Both drug treatments attenuated tumor
growth, and in some mice led to partial melanoma regression
suggesting that ALDHHigh subpopulations may be required to
support continued tumor growth (Figure S5A). These data sug-
gest that near-maximal drug absorption or efficacy may already
be achieved at 50 mg/kg.
Following treatment, we isolated the tumors and analyzed Al-
defluor activity in A375-L2Tmelanoma cells. Tumors treatedwith
nifuroxazide had reduced numbers of ALDHHigh cells evaluated
by Aldefluor assay, indicating that nifuroxazide can target
ALDHHigh subpopulations directly in the tumor (Figure 5C). Strik-
ingly, immunohistochemistry revealed that ALDH1High cells were
absent in tumors treated with nifuroxazide (Figures 5D and 5E),
accompanied by increased levels of cleaved caspase-3, an
apoptosis marker (Figures 5F and 5G). Therefore, nifuroxazide
does not just inhibit ALDH enzyme activity in cells, but specif-
ically eradicates ALDH1High tumor subpopulations.
To assess the phenotypic outcome of targeting ALDH1High
tumor-initiating subpopulations, we tested if melanoma cells
treatedwith nifuroxazide could initiate new tumors in serial trans-
plantation (Figure 5H). We removed tumors from mice that had
been treated with nifuroxazide or oil vehicle, FACS sorted
10,000 melanoma cells per tumor, and injected these into recip-
ient mice without further treatment. Melanomas from mice that
had been treated with the oil vehicle control rapidly grew tumors
while, in contrast, melanomas from nifuroxazide-treated tumors
were significantly inhibited in forming new tumors (Figure 5I).
These results were validated in tumors generated from A375
cells without the tdTomato marker, whereby, due to a lack of
fluorescence, melanoma cells were selected by excludingCell Chemical Biology 25, 1–14, December 20, 2018 7
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(A) Sensitivity of A375-L2T tumors to nifuroxazide in vivo. Mice were treated with 150 mg/kg nifuroxazide or vehicle for 9 continuous days. Values are means ±
SEM (n = 3 mice/condition; experimental replicates >3, *p < 0.05, two-way ANOVA with Sidak’s test).
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**p < 0.01; Student’s t test). Image of tumors from control or nifuroxazide-treated mice at the end of drug treatment duration.
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(legend continued on next page)
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zide effectively inhibits tumor growth in vivo by selectively
targeting ALDH1High subpopulations directly in the tumor, while
surviving ALDH1Low cells lack melanoma initiation potential,
and are unable to form new tumors.
Targeted Therapy Increases ALDHHigh Cells and
Sensitivity to Nifuroxazide
Little is known about the clinical importance of ALDH1High sub-
populations in human clinical samples that have recurred
following BRAF inhibitor (BRAFi) and/or MEK inhibitor (MEKi)
treatment. First, we performed immunohistochemistry for
ALDH1 isoforms on seven patient melanoma samples before
BRAFi treatment and in recurrent melanoma from the same pa-
tient. The ALDH1 antibody detects both ALDH1A1 and ALDH1A3
isoforms, and thus detects ALDH1 proteins that mark ALDH1High
subpopulations in melanoma (Luo et al., 2012). As shown in Fig-
ures 6A–6D, four of the melanomas that relapsed after treatment
showed a dramatic increase in the number of ALDH1-positive
cells and an increase in ALDH1 expression compared with their
matched pre-treatment samples. These observations indicate
that ALDH1High subpopulations may play an important role dur-
ing melanoma relapse for some patients.
Next, we tested the potential for nifuroxazide to synergize with
BRAF inhibitors. In cell culture, BRAFi lead to an adaptive in-
crease in the number of cells expressing stemness markers,
such as ALDHHigh 24 hr post-treatment (Figure 6E) (Ravindran
Menon et al., 2015). Building on these results, we found that
treatment with BRAFi dramatically increased the sensitivity of
A375 melanoma colonies to nifuroxazide (Figure 6F).
BRAF signaling depends onMEK activation, and the combina-
tion of BRAFi plusMEKi has improved clinical benefit for patients
with BRAF mutant melanoma (Luke et al., 2017). To establish if
BRAFi plus MEKi increases ALDH1 levels in melanoma, we
analyzed RNA sequencing (RNA-seq) data of a melanoma pa-
tient cohort before treatment and 12 ± 5 days into BRAFi plus
MEKi combined treatment (European Genome-phenome
Archive: S00001000992) (Kwong et al., 2015). Of nine patients,
six showed an increase in ALDH1A1 expression while on BRAFi
plus MEKi treatment (Figure 6G). These data indicate that for
some patients, BRAFi plus MEKi treatment is associated with
an increase in ALDH1A1 expression.
Next, we sought to address if vemurafenib (BRAFi) plus trame-
tinib (MEKi) treatment could lead to an increase in ALDH activity
in cell line models and provide a window of opportunity to syner-
gize with nifuroxazide. We found cell lines varied in response and
sensitivity to the combined treatment. A375 cells were highly(D) Immunohistochemistry staining of ALDH1A3 expression in melanoma tumors
(n = 3). 203. Scale bar, 100 mm. Arrows point to ALDH1High cell clusters. Mel, m
(E) Quantification of ALDH1A3-positive cells in melanoma tumors treated with
melanoma tumors treated with nifuroxazide or vehicle from 10 random fields of v
(F and G) Representative image of immunohistochemistry staining, 403. Scale ba
cells in tumors treated with nifuroxazide or vehicle (n = 3) (G). The percentage me
magnification is presented (**p < 0.01; Student’s t test).
(H) Schematic diagram of the experimental outline in (F) for nifuroxazide effect o
(I) Tumor-initiating potential of nifuroxazide- or control-treated tumors in recipien
6 days, tumors were removed and isolated A375-L2T cells were injected into re
condition).
See also Figure S5.sensitive to MEKi, and the addition of MEKi (2 nM) inhibited the
increase in ALDH activity promoted by the BRAFi. In contrast,
low concentrations of BRAFi (50 nM) plus MEKi (0.2 nM) lead
to an increase in Aldefluor activity in A375 cells (Figure 6H). In
C089 cells, BRAFi (1 mM) alone did not significantly increase
ALDH1 mRNA (Figure S6A), while the addition of MEKi alone,
or BRAFi plusMEKi, increased ALDH activity at all MEKi concen-
trations (0.04–2 nM) and was associated with an increase in
mRNA expression of ALDH1A1 (Figures 6H and S6A). Inhibition
of the MAPK pathway with MEKi did not increase ALDHHigh in
D38 NRASQ61K mutant cells at any concentration (0.04–30 nM)
(Figure 6H). These data indicate that BRAFi plus MEKi combined
therapy can lead to an adaptive increase in ALDHHigh subpopu-
lations in a subset of melanoma cell lines, although the underly-
ing drug sensitivities may vary. Ultimately, we tested if the
therapy-induced ALDH activity increase primed the cells for
sensitivity to nifuroxazide. We found that both A375 and C089
cell lines had increased sensitivity to nifuroxazide treatment
when combined with the low doses of BRAFi plus MEKi that
increase ALDH activity (Figure 6I). These results strengthen the
concept that targeted therapy leads to an adaptive increase in
ALDH1 in melanoma and provides an opportunity to treat with
nifuroxazide.
DISCUSSION
We discover that ALDH1 is a target for the widely used antibiotic
nifuroxazide, and that this mechanism selectively targets
ALDH1High cells to inhibit tumor growth and initiation potential.
Our results indicate that higher levels of ALDH1 activity in mel-
anoma are associated with increased sensitivity to nifuroxazide,
independent ofmelanoma genotype. Thismay permit cancer pa-
tient stratification for nifuroxazide responsiveness based on
ALDH1 activity. Analysis of TCGA RNA expression across tu-
mors reveals melanoma to be among the cancers with the high-
est ALDH1A3 overall expression (Figure S6B) (Cancer Genome
Atlas Network, 2015; Cerami et al., 2012; Gao et al., 2013b). Tar-
geting ALDH1High subpopulations may be especially important
for the 50% of melanoma patients that do not have BRAF muta-
tions and so far have limited options for targeted therapy (Luke
et al., 2017).
The clinical evidence we present here indicates that ALDH1-
High subpopulations increase from primary tumor to BRAFi-resis-
tant metastatic melanomas in some patients, suggesting that
melanoma cells may change their cellular state in response to
drug treatments. This is supported by analysis of the RNA-seq
dataset from patients that reveals some patient melanomasgenerated from A375-L2T cells treated with nifuroxazide or vehicle for 5 days
elanoma tumor. Dotted lines outline tumor.
nifuroxazide or vehicle. The percentage mean of ALDH1A3-positive cells in
iew with 103 magnification is presented (*p < 0.05; Student’s t test).
r, 50 mm (F) and quantification of cleaved caspase-3-positive cells of melanoma
an of cleaved caspase-3-positive cells from 10 random fields of view with 103
n tumor-initiating potential.
t mice. Mice with established tumors were treated with nifuroxazide or oil for
cipient mice without further treatment. Values are means ± SEM (n = 3 mice/
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Further analysis of a published RNA microarray dataset (GEO:
GSE35230) (Greger et al., 2012) of A375 clone 16R6-4
revealed that, despite being resistant to BRAFi plus MEKi,
combined treatment led to an increase in ALDH1A3 mRNA
expression, suggesting that resistant cells are still sensitized to
therapy, and that ALDH1 expression may contribute to resis-
tance mechanisms (Figure S6C). This drug-induced increase in
ALDH1 protein andmRNA underscores the importance in target-
ing ALDH1High cells, and suggests that an important therapeutic
window may be during or following targeted therapy.
Because ALDHHigh subpopulations are present in many can-
cer types, major efforts are underway to generate ALDH1
isoform-specific inhibitors. Given that 19 ALDH enzymes are
present in the human genome (including at least 6 within the
ALDH1 family) (Koppaka et al., 2012), it is not clear at this stage
if specific ALDH1 isoform inhibitors will be sufficient to effectively
target ALDHHigh subpopulations in human cancers, or if other
ALDH isoforms might be able to compensate and lead to drug
resistance. By contrast, we show that nifuroxazide has a two-
hit mechanism, whereby it first inactivates ALDH1 through its
bio-activation, and, secondly, the bio-activated species gener-
ates cytotoxicity to kill the cell. Therefore, rather than transiently
inhibiting ALDH1High activity, nifuroxazide selectively kills
ALDH1High subpopulations.
Nifuroxazide has been commonly used to treat intestinal infec-
tions such as colitis and diarrhea. Bio-activation of 5-nitrofurans
in bacteria and trypanosomes generates reactive nitro metabo-
lites and causes DNA damage. Repurposing nifuroxazide as an
anti-cancer drug will require the identification of a therapeutic
window that selectively targets ALDH1High cells in cancer without
eradicating ALDH1High stem cell populations in somatic tissues.
Evidence from clinical use of nifuroxazide indicates that nifurox-
azide is generally well tolerated (Begovic et al., 2016; Bouree
et al., 1989). Nifuroxazide is administered at 800 mg/day in hu-
man patientswhen used as an antibiotic, while in veterinarymed-
icine, animals are often treated at 50 mg/kg, and higher doses
(>200 mg/kg) have been described in animals without side ef-
fects (Cagliero, 1976; Gao et al., 2013a). We find nifuroxazide
is well tolerated in mice at 50 and 150 mg/kg, with no signs of
side effects or weight loss. All drug administrations in our in vivo
studies are oral, as administered for patients when used as an
antibiotic. This is a similar dose range used for nifurtimox,
which is used at 800 mg/day for trypanosome infection (albeit
for 30–90 days), 150 mg/kg/day for pre-clinical neuroblastoma
xenograft studies for 28 days (Saulnier Sholler et al., 2009),
and at 30 mg/kg/day for cancer treatment (NCT00601003) (Saul-(E) Representative flow cytometry histograms of Aldefluor activity in A375 cells t
(F) Sensitivity of A375 colonies in soft agar to nifuroxazide in combination w
nett’s test).
(G) Pair-matched FPKM fold change of melanoma ALDH1A1 and ALDH1A3
pre-treatment, based on the RNA-seq data retrieved from the European G
values are present as means ± SEM. FPKM, fragments per kilobase of tr
(H) Aldefluor activity of melanoma cell lines treated with BRAFi plus trametinib (ME
MEKi), C089 (1 mM BRAFi + 0.04 nM MEKi), or D38 (0.04 nM MEKi).
(I) Representative flow cytometry analysis demonstrating percentage of Annexi
and 0.2 nM MEKi for 48 hr (n = 2). C089 treated with 5 mM nifuroxazide, 1 mM BR
See also Figure S6.nier Sholler et al., 2011). While we cannot directly compare the
pharmacokinetics of nifurtimox with nifuroxazide, our studies
suggest that nifuroxazide may be effective at targeting ALDH1-
High cells in a clinically relevant dose range. Importantly, if the
combined BRAFi (plus MEKi) and nifuroxazide drug synergy
we observe in cell culture holds true in the clinical setting, this
may reveal BRAFi (plus MEKi) and nifuroxazide to be a highly
beneficial drug combination and permit lower drug doses with
reduced overall drug toxicity.
Despite the evidence for melanoma subpopulations in cancer
progression and drug resistance, there is an absence of drugs
that specifically target phenotypic tumor-initiating cell popula-
tions available in the clinic. Indeed, despite the use of nifurti-
mox in patients with neuroblastoma and medulloblastoma,
the mechanism for the anti-cancer activity is unknown. Given
that ALDH1High activity marks functional stem cell properties
in neuroblastoma (Flahaut et al., 2016; Hartomo et al., 2015),
ALDH1High activity might mediate nifurtimox anti-cancer
activity. Alternatively, the high levels of ALDH2 in neuroblas-
toma may mediate sensitivity to nifurtimox (TARGET, 2018). Ni-
furtimox side effects include a disulfiram-like reaction to
alcohol, suggesting that nifurtimox activity may be preferentially
bio-activated by ALDH2. This is consistent with our observa-
tions that nifurtimox is a competitive substrate for ALDH2
(Zhou et al., 2012) and that nifuroxazide is selective for
ALDH1. Understanding the mechanism of nifurtimox anti-can-
cer effects may permit patient stratification protocols based
on ALDHHigh activity in the tumor or ALDH2 patient genotypes.
In summary, we have provided substantial mechanistic in-
sights into how a specific 5-nitrofuran used as an antibiotic
can act through ALDH1 to reduce melanoma initiation and pro-
gression. We believe that such insights are critical to expand
the pipeline of cancer drug discovery as it allows us to rationally
reposition existing drugs for therapy. The discovery that ALDH1
is a target for nifuroxazide, and that this enables the specific
killing of ALDH1High melanoma cells, goes beyond approaches
of reducing the tumorigenic potential of such cells by interfering
with their ALDH1 activity, which may be limited and transient.
This is an important alternative therapeutic strategy to target
phenotypically distinct tumor-initiating populations that
contribute to melanoma growth and are marked by ALDH1High
activity.
SIGNIFICANCE
One of the major challenges for cancer treatment and ther-
apeutic design is intratumor heterogeneity, shaped in partreated with vemurafenib (BRAFi) or DMSO control (n = 2).
ith BRAFi. Values are means ± SEM (n = 2, *p < 0.05, ANOVA with Dun-
in BRAF and MEK inhibitor-treated patient samples on-treatment versus
enome-phenome Archive S00001000992 database. Collective fold-change
anscript per million mapped reads.
Ki), or DMSO control 24 hr post-treatment (n = 3). A375 (50 nM BRAFi + 0.2 nM
n V-positive cells. A375 cells treated with 10 mM nifuroxazide, 50 nM BRAFi,
AFi, or 0.04 nM MEKi for 48 hr (n = 2).
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anoma, and in many other cancers, high levels of ALDH
activity (ALDH1High) mark a subpopulation of cells with
increased tumor-initiation potential and cancer stem cell
properties. Here, we show that ALDH1 is a target for 5-nitro-
furan pro-drugs that are widely used to treat bacteria infec-
tions, and that have recently been shown to have anti-cancer
potential.
We have previously shown that 5-nitrofurans are bio-acti-
vated by ALDH2, the enzyme responsible for alcohol meta-
bolism. We now show that the 5-nitrofuran, nifuroxazide, is
selective for ALDH1, and that the cytotoxic mechanism of
action in melanoma cells is mediated by eradicating
ALDH1High subpopulations. This is significant because no
clinically available drugs have so far emerged to specif-
ically eradicate ALDH1High subpopulations. We show that
ALDH1High subpopulations are enriched in patients with
recurrent melanoma following BRAF inhibitor treatment
and that ALDH1A1 mRNA is increased in patient
melanomas during BRAF plus MEK inhibitor treatment.
We demonstrate that nifuroxazide activity in melanoma
cells is via a two-hit mechanism: bio-activation by ALDH1
leads to toxicity in cells, coupled with oxidation and inhibi-
tion of ALDH1. Thus, unlike ALDH inhibitors, we discover
that bio-activation of 5-nitrofuran pro-drugs can selectively
kill ALDH1High cell populations. Targeting subpopulations in
melanoma based on the distinctive phenotypic properties
of tumor-initiating (stem) cells, rather than targeting
the molecular activity of cancer mutations, is an orthogonal
therapeutic approach to current targeted and immune
therapies.STAR+METHODS
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Antibodies
Rabbit poly-clonal ALDH1A3 antibody Invitrogen Cat#PA5-15000; RRID:AB_2224038
Mouse mono-clonal GAPDH antibody Abcam Cat#Ab8245; RRID:AB_2107448
Mouse ALDH1 BD biosciences Cat#611194; RRID:AB_2224312
Cleaved Caspase-3 (Asp175) (5A1E) Rabbit mAb Cell Signaling Cat# 9664; RRID:AB_2070042
Goat anti mouse IRDye 680 secondary antibody LI-COR Biosciences Cat#925-68070; RRID:AB_2651128
Goat anti rabbit IRDye 800 secondary antibody LI-COR Biosciences Cat#925-32211; RRID:AB_2651127
CD271-PE Miltenyi Biotec Cat# 130-112-790
FITC anti-mouse CD45 Antibody BioLegend Cat# 103107; RRID:AB_312972)
PE anti-mouse H-2Kb Antibody BioLegend Cat#116507; RRID:AB_313734
APC anti-mouse CD31 Antibody BioLegend Cat# 102409; RRID:AB_312904
Bacterial and Virus Strains
One Shot Stbl3 Chemically Competent E. coli Invitrogen Cat#C737303
Biological Samples
Human melanoma tissue Patient samples were collected by
Melanoma Program at the University
of Pennsylvania under Institutional
Review Board (IRB) approval Protocol
#703001 and Abramson Cancer
Center’s Protocol # UPCC 08607.
Chemicals, Peptides, and Recombinant Proteins
Acetic acid Sigma-Aldrich Cat#71251
NFN1 Maybridge Cat#BTB05727SC
Nifuroxazide EMD Millipore Cat#481984
Daidzin Sigma-Aldrich Cat#30408
Disulfiram BioVision Cat#2308
Nitrofurantoin Sigma-Aldrich Cat#67-20-9
Nifurtimox Sigma-Aldrich Cat#N3415
Furazolidone Sigma-Aldrich Cat#F9505
Vemurafenib LKT-Labs Cat#029872-54-5
DEAB STEMCELL technology Cat#01705
Propidium iodide Roche Cat#11348639001
DAPI Sigma-Aldrich Cat#D9542
RIPA Lysis buffer (10x) Sigma-Aldrich Cat#20-188
Collagenase D Roche Cat#11088858001
Ammonium Chloride Solution STEMCELL Technology Cat#07850
Annexin V, Alexa Fluor 555 conjugate Thermo Fisher Scientific Cat#A35108
HEPES Sigma-Aldrich Cat#7365-45-9
Cell Dissociation Solution Non-enzymatic Sigma-Aldrich Cat#C5914
Complete Protease inhibitor Thermo Fisher Scientific Cat#A32953
T4 DNA Ligase New England Biolabs Cat#M0202M
T4 DNA Ligase Reaction Buffer New England Biolabs Cat#B0202S
Human Recombinant ALDH1A1 Life Technologies Cat#11388H07E25
Human Recombinant ALDH1A3 Life Technologies Cat#11636H07E5
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Human Recombinant ALDH2 BioVision Cat#6332
Matrigel Growth Factor Reduced Corning Cat#356230
EGF Thermo Fisher Scientific Cat#PHG0313
FGF-Basic R&D Cat#233-FB-025/CF
B27 Supplement Thermo Fisher Scientific Cat#17504044
Low Melting Agarose Sigma-Aldrich Cat#A4018
Trametinib Selleckchem Cat#S2673
Critical Commercial Assays
Aldefluor Assay STEMCELL technology Cat#01705
Cell Meter APC-Annexin V Binding Apoptosis Assay Kit AAT Bioquest Cat# 22837
Draq7 Abcam Cat#Ab109202
IncuCyte NucLight BacMam 3.0 Essen Bioscience Cat#4622
Bond Polymer Refine Red Detection System Leica Biosystems Cat#DS9390
Dako REALTM EnVisionTM Detection System,
Peroxidase/DAB+, Rabbit/Mouse
DAKO Cat#K5007
DAKO Protein block serum-free DAKO Cat#X0909
Sulforhodamine B sodium salt (SRB) Sigma-Aldrich Cat#S1402
Bradford Assay Bio-Rad Cat#500-0006
Lipofectamine RNAiMAX Transfection Reagent Invitrogen Cat#13778150
Lipofectamine 3000 Transfection Reagent Invitrogen Cat#L3000008
Polyethylenimine, Linear, MW 25000, Transfection Grade Polysciences Cat#23966-1
Experimental Models: Cell Lines
A375 ATCC Cat#CRL-1619; RRID:CVCL_0132
293T ATCC Cat#CRL-3216; RRID:CVCL_0063
C077 ABN Cell Line Bank, QIMR
Berghofer Medical Research
Institute
C089 ABN Cell Line Bank, QIMR
Berghofer Medical Research
Institute
C092 ABN Cell Line Bank, QIMR
Berghofer Medical Research
Institute
MEWO ABN Cell Line Bank, QIMR
Berghofer Medical Research
Institute
D38 ATCC
Experimental Models: Organisms/Strains
Mouse: NOD SCID Charles River RRID:IMSR_ARC:NODSCID
Oligonucleotides
siRNA sequence; Silencer Select; ALDH1A3,
GUAUCGAAGAAGUGAUAAA
Life technology Cat#4390824
gRNA sequence, ALDH1A3;
CACCGCTACATGTAACCCTTCAACT
This paper N/A
Recombinant DNA
ALDH1A3 human cDNA clone pCMV6-XL4 vector Origene Cat#SC119706
pCMV6-XL4 vector Origene Cat#PCMV6XL4
lentiCas9-Blast vector (Sanjana et al., 2014) Addgene; 52962
lentiGuide-Puro vector (Sanjana et al., 2014) Addgene; 1000000049
(Continued on next page)
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pCMVPAX2 (Lang et al., 2000) Addgene; 36052
VSV.G (Reya et al., 2003) Addgene; 14888
Software and Algorithms
MaxQuant version 1.5.7.4 http://www.coxdocs.orgi
Uniprot Human Proteome, Release 2017_02 http://www.uniprot.org/proteomes/
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Further information and requests for reagents should be directed to the corresponding author E. Elizabeth Patton (e.patton@igmm.
ed.ac.uk).
EXPERIMENTAL MODEL DETAILS
Chemicals
Vemurafenib (LKT labs), Trametinib (Selleckchem), Nifuroxazide (EMD Millipore), NFN1 (Maybridge), and clinical 5-nitrofurans were
prepared as 100mMsolutions in 100%dimethyl sulfoxide (DMSO). NFN1.1was generated in house following Zhou et al., 2012.Work-
ing solutions were freshly prepared before addition to the cell media.
Cell Lines
A375 cells were obtained from America Type Culture Collection (ATCC). To generate A375-L2T cells, A375 cells were transfected
with ubiquitin promoter-driven L2T (pFU-L2T) and sorted by flow cytometry every week for 3 weeks. L2T lentivirus vector was kindly
given by Dr. Sanjiv S. Gambhir (Stanford University) toM.F. through anMTA. DMEMmedium, l-glutamine, penicillin/streptomycin and
fetal bovine serum (FBS) were purchased from Life Technologies. Cells were maintained in DMEM medium supplemented with
5mg/mL1 l-glutamine, 1% penicillin/streptomycin and 10% FBS and cultured in a humidified 5% CO2 incubator at 37C. C077,
C092, C089, and MEWO cells were maintained in RPMI-1640 medium (Life Technologies, Thermo Fisher Scientific) supplemented
with 1% penicillin/streptomycin and 10% FBS and cultured in a humidified 5% CO2 incubator at 37
C. All cell lines are routinely
tested for mycoplasma by PCR every three months (date of last test June 20, 2018).
In Vivo Animal Studies
Female 6–8 week-old NOD/SCID mice were purchased from Charles River Laboratories. Mice were used for tumor xenograft and
drug treatment studies.Micewere housed in individually ventilated cages (IVC) in groups of 5-6mice per cage. All animal experiments
were approved by the University of Edinburgh Animal Welfare and Ethical Review Body (approval PL01-16) and the UK Home Office
(PPL 70/8897).
METHOD DETAILS
Generation of ALDH1A3 Mutant Lines Using CRISPR/Cas9
We used two vector system in which the LentiCas9-Blast vector (Addgene; 52962) contained the human codon-optimized Strepto-
coccus pyogenes Cas9-expression cassette and the LentiGuide-Puro (Addgene; 1000000049) contained the gRNA expression
cassette. The lentiviral vector was produced by transfection of 293T (ATCC) cells with the lentiviral vector plasmid and packaging
plasmids pCMVPAX2 (Addgene; 36052) and VSV-g (Addgene; 14888) with polyethylenimine transfection reagent following manufac-
turer’s instructions. 24 hours post transfection, the medium was replaced with fresh media and the cells were cultured for 48 hours.
The lentiviral vector containing supernatant was filtered (0.45mm filter) and A375 cells (1 3 104 cells) were transduced with 2ml of
LentiCas9-Blast virus particles in 5ml culture media and 5mg polybrene. Transduced cells were selected with 1ng/ml blasticidin to
obtain stable cell line expressing Cas9 (A375-Cas9).
SgRNA sequence was cloned in to LentiGuide-Puro. To this, oligos (100mM) were annealed and phosphorylated in 13 T4 ligation
buffer with 13 T4 PNK (New England Biolabs) and were ligated into the BsmB1 site of the LentiGuide-Puro vector. One ShotTM
Stbl3TM chemically competent E. coli were transformed by adding 100ng of DNA and heat-shocked for 45 seconds at 42C. Sample
was spread on agar with puromycin plates and incubated for 24 hours and single colonies were selected.
SgRNAs were expressed by a transient transfection of the A375-Cas9 cells with LentiGuide-Puro vector described above. Briefly,
5 3 104 A375-Cas9 cells were plated in a 6 well/plate. After 24 hours A375-Cas9 cells were transfected with ALDH1A3-LentiGuide-
Puro using Lipofectamine 3000 (0.3ml/well) (Invitrogen) and P3000 reagent (0.2ml/well). Medium was changed after 24 h. 48 h later,
0.8 mg/ml puromycin (Sigma) was added into transfected cells. Single-cell clones were isolated for sequencing and positive clones
(ALDH1A3Cpr3, and ALDH1A3Cpr21) were expanded in culture.Cell Chemical Biology 25, 1–14.e1–e6, December 20, 2018 e3
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A375 cells were seeded in 96 well plat at 2.5 3 103 cells/well and incubated for 24 hours. Cells were treated 0.1mg ALDH1A3 over-
expressing vector (ALDH1A3/pCMV6-XL4) (Origene) or pCMV6-XL4 empty vector (control) in Opti-MEMmedia with Lipofectamine
3000 (0.3ml/well) (Invitrogen) and P3000 reagent (0.2ml/well). Medium was changed after 72 hours.
siRNA Transfection
A375 cells were seeded in 96-well plate at a density of 2.5 3 103 cells/well or in 6-well plate at a density of 5 3 104 cells/well and
incubated for 24 hours. Cells were then treated with 5pmol ALDH1A3 siRNA or scrambled control in Opti-MEM media with
Lipofectamine RNAiMAX (1.5ml/well)(Invitrogen). Medium was changed after 96 hours.
Flow Cytometry and Aldefluor Assay
The aldehyde dehydrogenase (ALDH) enzyme activity was measured using the ALDEFLUOR assay kit (STEMCell Technology) ac-
cording to themanufacturer’s protocol. In brief, cells were incubatedwith the fluorescent bodipy-aminoacetaldehyde (BAAA) reagent
for 30 minutes at 37C. As a negative control, ALDH enzyme activity was blocked using diemethylamino-benzaldehyde (DEAB). Al-
defluor activity wasmeasured using FACS Fortessa (BDBiosciences). For cell sorting, the Aldefluor stained cells were analyzed using
the FACSAria II (BDBiosciences) and the top 5%of cell population with highest ALDH activity (ALDHHigh cells), detected on the green
fluorescence channel (515–545 nm), and the bottom 5%of cells with lowest ALDH activity (ALDHLow cells) were cell sorted. Datawere
analyzed using FlowJo software program. Dead cells were excluded using Propidium iodide (PI, 13mM, Roche) or 40,6-Diamidine-
20-phenylindole dihydrochloride (DAPI, 3mM, Sigma-Aldrich).
Cell Viability Assay
Cytotoxicity of the 5-nitrofurans on melanoma cell lines was determined using the sulforhodamine-B (SRB) cytotoxicity assay
(Sigma-Aldrich). 1000 cells per well were plated in 96-well plates overnight. Cells were then treated either with a vehicle control
(DMSO) or increasing concentrations of compounds (1nm - 100mM) for 72 hours. SRB assay was carried out as described previously
(Skehan et al., 1990). In brief, cells were fixed with Trichloroacetic acid for 1 hour at room temperature, followed by 0.4% SRB for
30 minutes at room temperature. Plates were then washed and the SRB was dissolved by 10mM Tris buffer and read at 570nm
on a microplate reader. Experiments were performed in three independent series and the mean half maximal effective concentration
(EC50) was used to compare cytotoxicity.
Cytotoxicity and Apoptosis Assays Using IncuCyte ZOOM Live-Cell Imaging System
IncuCyte ZOOMLive-Cell Imaging system (Essen Bioscience) was used for kinetic monitoring of cytotoxicity and apoptotic activity of
Nifuroxazide or NFN1 on melanoma cells. 1000 cells/well were seeded in 96 well plate and allowed to attach overnight. Cells were
treated with increasing concentrations (1nm - 100mM) of compounds in the presence of Draq7 (3mM, Abcam) and IncuCyte
NucLight BacMam 3.0 (2% v/v) (Essen Bioscience). Draq7 stains the nuclei in dead and permeabilized cells and IncuCyte
NucLight BacMam 3.0 enables nuclear labelling of living cells. Plates were scanned and fluorescent and phase-contrast images
were acquired in real time every 3 hours from 0 to 72 hours post treatment. Normalized green and red object count per well was quan-
tified at each time point and time-lapse curves were generated by IncuCyte ZOOM software. Ratios of Draq7level in treated cells
compared to vehicle were plotted in Microsoft Excel.
Apoptosis Detection Using Annexin V/PI
105 cells were seeded in 6-well plates overnight. Cells were then treated with compounds or vehicle for 48 hours. For detection of
apoptotic cells, cells were dissociated with cell dissociation buffer and 500ml of binding buffer was added to each sample followed
by 5mg/ml of Annexin V–FITC and 5mg/ml of PI. Samples were gently vortexed and incubated for 15 minutes at room temperature in
the dark. Samples were analysed using FACS Fortessa (BD Biosciences).
Colony Formation Assay in Soft Agar
5000 cells were suspended in serum free DMEMmedia supplemented with 10ng/ml EGF, 10ng/ml FGF, B27 supplement (1x, Thermo
Fisher Scientific), 5mg/mL1 l-glutamine, and 0.3% low melting agarose (Sigma-Aldrich) in the presence or absence of compounds.
Cells were then layered over a solid base of 0.5% low melting agarose in 35mm plastic dishes. The cultures were incubated at 37C
for 12 days. Colonies (>6 cells) from 10 separate fields were counted using a microscope with a 4X objective.
Sphere Formation Assay and Differentiation Assay
1000 sorted ALDHHigh and ALDHLow cells were cultured in serum free DMEMmedia supplemented with 10ng/ml EGF, 10ng/ml FGF,
B27 supplement (1x), 5mg/mL1 l-glutamine and then plated in low adhesion round bottom plates (Corning). Cell proliferation was
measured by counting disaggregated single cells using a haemocytometer. Dead cells were excluded by using 0.4% Trypan blue
solution (Sigma-Aldrich).
For differentiation assay, cell sorted ALDHHigh and ALDHLow cells were cultured in serum containing (10% FBS) DMEM media
supplemented with 5mg/mL1 l-glutamine, 1% penicillin/streptomycin and cultured in tissue culture plates for 5 days. Differentiation
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Cells were plated at 100,000 cells/well in 6-well plates and allowed to adhere overnight. Cells were lysed with RIPA lysis buffer
(Sigma-Aldrich), supplemented with a complete protease inhibitor (Thermo Fisher Scientific Inc.). Protein concentrations were deter-
mined using the Bradford assay (Bio-Rad Laboratories) and 25mg protein per lane was electrophoresed on a 12% SDS-polyacryl-
amide gel in running buffer (Bio-Rad). Gelswere transferred onto nitrocellulosemembranes using the semi-dry Turbo Transfer system
with Turbo Transfer buffer (Bio-Rad). Membranes were probed using rabbit poly clonal ALDH1A3 (1:1000, Invitrogen), and GAPDH
(1:5000, Abcam) followed by goat anti-rabbit IRDye 680- or 800- labelled secondary antibodies (LI-COR Biosciences). Membranes
were imaged using an Odyssey infrared scanner (LI-COR Biosciences).
In Vivo Studies
The tumorigenicity of ALDHHigh vs ALDHLow cells was compared by injecting 50 A375 sorted cells suspended in 100ml of HBSS con-
taining 30%matrigel (Corning). Cells were introduced via subcutaneous injection to the right flank of mice. Tumor size wasmeasured
twice a week with a calliper.
To evaluate the cytotoxicity of nifuroxazide in vivo, NOD/SCID mice were injected with 10,000 A375-L2T cells in 30% matrigel via
subcutaneous injections. Once tumors were established, animals were allocated to experimental group randomly so that the average
tumor size within the experimental group would be the same. Mice were treated with vehicle or 150mg/kg or 50mg/kg nifuroxazide
suspended in sunflower oil via oral gavage each day. For serial transplantation studies, once drug treatment was completed, tumors
were removed and digested into single cells. For tumor digestion, tumors were minced with a surgical blade and single cell suspen-
sions were generated by enzymatic digestion with 2mg/ml Collagenase D (Roche) for 1 hour at 37C with intermittent vortexing, fol-
lowed by passage through 40mmfilters (Fisher Scientific). Red blood cells were lysed using Ammonium chloride solution (STEMCELL
technology). Cells were washed twice and A375-L2T cells were cell sorted using FACS Aria. 10,000 sorted A375-L2T cells excised
from vehicle treated (DMSO) tumor or nifuroxazide treated tumor was suspended in HBSS containing 30% standard matrigel and
injected subcutaneously into 6-8 weeks old NOD/SCOD mice. Tumor growth was measured twice a week using calliper.
Immunohistochemistry
Paraffin-embedded tissue samples were first de-paraffinized in xylene and re-hydrated in gradedwashes of ethanol andwater. Sam-
ples were boiled in pre-warmed 10mM sodium citrate (pH 6.0) for 10 minutes, followed by incubation in 3% H2O2 for 20 minutes and
blocked in DAKO Protein Block Serum-Free (DAKO Agilent pathology solutions) for 1 hour at room temperature. Samples were
incubated with ALDH1A3 (1:10000, invitrogen) overnight at 4C, followed by HRP-conjugated secondary antibodies (Jackson
ImmunoResearch Laboratories). Slides were counterstained with Mayer’s hematoxylin for 5 minutes.
Patient samples were strained using Leia Bond-IIIinstrument using the IHC J protocol with Bond Polymer Refine Red Detection
System (Leica Microsystems). Antigen retrieval was performed using ER1 solution (Leica Microsystems) for 20 minutes. Sections
were then incubated with ALDH1 at 1:300 (BD Biosciences) for 15 minutes, followed by 20 minutes post-primary AP and 30 minutes
incubation with polymer AP. Sections were then incubated with Bond Polymer Refine Red Detection System for 15 minutes and
counterstained with hematoxylin for 5min. Slides were washed three times between each step with either bond wash buffer or water.
ALDH1A3 and ALDH2 In Vitro Activity Assay
The ALDH1A3 in vitro activity assay was conducted using commercially bought ALDH1A3 (Life Technologies), and purified ALDH2-
His was synthesized in-house was used for ALDH2 (see below). ALDH (5ug) was pre-incubated at 25C in 50mM sodium phosphate
buffer (pH7.4), 0.4mM NAD+ and drug (1mM NFN1, NFN1.1; 10mM nifuroxazide) or vehicle (1% DMSO) for 10 minutes. Disulfiram or
Daidzin (10mM; ALDH1A3 & ALDH2 respectively) was used as a negative control. The assay was initiated by the addition of 0.4mM
acetaldehyde. NADH turnover was measured using NanoDrop 2000 UV-Vis spectrophotometer at 340nm ( 3= 6.22mM/cm) after
10mins to determine ALDH activity against DMSO. Normalized ANOVA were used for statistics.
ALDH2 Protein Purification and Activity
Expression from pTrcHis-TOPOHis-tagged human ALDH2 plasmid was achieved through transformation of the plasmid into BL21*
E. coli and transduction with 1mM Isopropyl b-D-1-thiogalactopyranoside (IPTG). Proteins were extracted through Constant
ONESHOT Cell Disruption lysis and lysates, then centrifuged. ALDH2-His was purified on A¨KTApurifier UPC 100, first through
the HiTrap IMAC FF 1mL column and then through size exclusion using HiLoad 16/600 Superdex 200 pg size exclusion.
ALDH expression was confirmed by gel chromatography and purified ALDH fractions pooled together.
Purified His-tagged ALDH2 (5mg) was pre-incubated at 25C in 50mM sodium phosphate buffer (pH7.4), 2.5mM NAD+ plus
logarithmic dilution of 5-nitrofuran (NFN1 or NAZ) or 1% DMSO for 10mins. The assay was initiated by the addition of 2.5mM acet-
aldehyde. NADH turnover was measured using Spectramax M5 plate reader at 340nm ( 3= 6.22 mM-1 cm-1) for a total of 30mins to
determine ALDH activity. The enzymatic rate (V) and IC50 values determined were determined using the initial linear change of
absorbance between 60 – 300secs. Daidzin (10mM) was used as a positive control and NFN1.1 (10mM) as a negative control.
In Silico Modeling ALDH1A3 with Nifuroxazide
Watermolecules and other hetero atomswere removed from the structure of ALDH1A3 (PDB 5FHZ) and the programPDB2PQR2.1.1
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signed to compound structures using OpenBabel 2.4.1, utilising the -p option to predict the protonation states of functional groups
at pH 7.4. The MGLTools utility prepare_ligand4.py was used to assign Gasteiger charges and rotatable bonds. Autodock 4.2.6 was
used to automatically dock the compounds into the retinoic acid binding pocket of the crystal structure. A grid box that encompassed
the maximum dimensions of the cognate ligand plus 12 A˚ in each direction was used. The starting translation and orientation of the
ligand and the torsion angles of all rotatable bonds were set to random. The Autogrid grid point spacing was set at 0.2 A˚. The Au-
todock parameter file specified 50 Lamarckian genetic algorithm runs, 7,625,700 energy evaluations and a population size of 300.
Mass Spectrometry Analysis
To analyze ALDH-5-nitrofuran interactions by mass spectrometry, complexes for analysis were formed from 10.0mM of the ALDH
isoenzyme with 100mM compound in 2% (v/v) DMSO (final) with or without 500mM NAD+ and incubated for 1 hour at room temper-
ature in 10mMHEPES, pH7.5. Samples (2mL) were injected using an Agilent 1200SL HPLCwith a low rate of 0.3mL/min consisting of
70% H2O and 30% acetonitrile with 0.1% formic acid into an Agilent 6520 quadrupole-time of flight (Q-TOF) mass spectrometer
operating in TOF mode. The spectra were extracted and deconvoluted using the software packages MassHunter (B.08.00) and Bio-
confirm (B.08.00). The abundance levels of the peaks were calculated on the individual deconvoluted spectra using the Bioconfirm
(B.08.00) software package.
To analyze the oxidation of ALDH cysteines by 5-nitrofuran, first all unmodified cysteineswere alkylated to prevent oxidation during
the processing: cysteines already oxidized would not be alkylated, and instead would cascade towards the triply oxidized cysteine
sulfonic acid. Next, ALDH1A1 was digested into peptides, and the modified and unmodified peptides were identified on an Agilent
Model 6520 QTOF. Proteins from the in vitro reaction were suspended in a digest buffer with a final concentration of 0.8 M Urea,
10mM dithiotreitol and 100mMTris-HCl pH 7.5. Protein solutions were then incubated for 30 minutes at 50C. Reduced cysteine res-
idues were alkylated by adding iodoacetamide solution to a final concentration of 50mM and incubated 30 minutes at room temper-
ature, in the dark. Proteins were digested with by adding 0.1mg Trypsin and GluC 0.1mg (Promega) per sample for 16 hours at 37C.
Trypsin activity was inhibited by acidification of samples to a concentration of 1% TFA. Digests were desalted on C18 Stage tips and
eluates were analysed by HPLC coupled to a Q-Exactive mass spectrometer as described previously (Turriziani et al., 2014). Pep-
tides and proteins were identified and quantified with the MaxQuant software package (1.5.7.4), and label-free quantification was
performed by MaxLFQ (Cox et al., 2014). The search included variable modifications for oxidation (M, C, Y, W), dioxidation of
(M,C,W), trioxidation (C), carbamidomethylation (C) and carbamidomethylation+oxidation (C) as variablemodifications. The false dis-
covery rate, determined by searching a reverse database, was set at 0.01 for both peptides and proteins. Peptide oxidations were
relatively quantified by [PeptideOX]/[Peptides].
QUANTIFICATION AND STATISTICAL ANALYSIS
Graphpad Prism software was used for statistical analyses. Statistical and quantification details of experiments can be found in the
figure legends. Data are presented as ±SEM of at least 3 independent experiments. Significance was defined a p<0.05 between
comparison groups.e6 Cell Chemical Biology 25, 1–14.e1–e6, December 20, 2018
